Type 2 innate lymphoid cells inhibit the differentiation of osteoclasts and protect from ovariectomy-induced bone loss.

Bone loss Cytokines ILC2 Osteoclasts Osteoimmunology Type 2 innate lymphoid cells type

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
07 2020
Historique:
received: 30 08 2019
revised: 25 03 2020
accepted: 26 03 2020
pubmed: 3 4 2020
medline: 22 6 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

While the role of T cells in the regulation of bone homeostasis is well defined, little is known about the role of innate lymphoid cells (ILCs) on bone. ILCs are innate immune cells that share cytokine expression patterns with T cells but lack the T cell receptor. In this study we show that type 2 ILCs (ILC2) potently inhibit the generation of bone resorbing osteoclasts in vitro as well as favorably influence bone homeostasis under steady state conditions in vivo using loss and gain of function models. Furthermore, adoptive transfer of ILC2 completely abrogated ovariectomy-induced bone loss by significantly down-regulating osteoclast numbers in vivo. The suppressive effects of ILC2s on osteoclasts in vitro and in vivo as well as the protection from ovariectomy-induced bone loss were linked to their expression of IL-4 and IL-13 as well as STAT6 activation on the myeloid target cell, since deletion of IL-4/IL-13 in ILC2s or STAT6 in osteoclast precursors abrogated the anti-osteoclastogenic effect of ILC2s. Taken together, these findings show that ILC2 have to be considered as potent regulators of bone homeostasis.

Identifiants

pubmed: 32240850
pii: S8756-3282(20)30115-0
doi: 10.1016/j.bone.2020.115335
pii:
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115335

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no competing interests.

Auteurs

Yasunori Omata (Y)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; Department of Orthopaedic Surgery, The University of Tokyo, Tokyo, Japan; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Michael Frech (M)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Sébastien Lucas (S)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Tatjana Primbs (T)

Department of Internal Medicine 1, University of Erlangen-Nuremberg, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Lisa Knipfer (L)

Department of Internal Medicine 1, University of Erlangen-Nuremberg, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Stefan Wirtz (S)

Department of Internal Medicine 1, University of Erlangen-Nuremberg, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Yuho Kadono (Y)

Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan.

Taku Saito (T)

Department of Orthopaedic Surgery, The University of Tokyo, Tokyo, Japan.

Sakae Tanaka (S)

Department of Orthopaedic Surgery, The University of Tokyo, Tokyo, Japan.

Kerstin Sarter (K)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Georg Schett (G)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany.

Mario M Zaiss (MM)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Germany. Electronic address: mario.zaiss@uk-erlangen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH